Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis

References

• Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):1–37. doi:10.1038/s41572-018-0041-4.
   PubMedGoogle Scholar
• Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer‐Gould A. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019;6(9):1905–1922. doi:10.1002/acn3.50862.
   PubMed Web of Science ®Google Scholar
• Marrodan M, Alessandro L, Farez MF, Correale J. The role of infections in multiple sclerosis. Mult Scler. 2019;25(7):891–901. doi:10.1177/1352458518823940.
   PubMed Web of Science ®Google Scholar
• Tarlinton RE, Khaibullin T, Granatov E, Martynova E, Rizvanov A, Khaiboullina S. The interaction between viral and environmental risk factors in the pathogenesis of multiple sclerosis. IJMS. 2019;20(2):303. doi:10.3390/ijms20020303.
   Google Scholar
• Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Sci. 2022;375(6578):296–301. doi:10.1126/science.abj8222.
   PubMed Web of Science ®Google Scholar
• Yin JX, Tang Z, Gan Y, Li L, Shi F, Coons S, Shi J. Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis. Neuropharmacology. 2014;81:1–5. doi:10.1016/j.neuropharm.2014.01.027.
   PubMed Web of Science ®Google Scholar
• Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3(1):31. doi:10.1186/s40168-015-0094-5.
   PubMedGoogle Scholar
• Ghezzi L, Cantoni C, Pinget GV, Zhou Y, Piccio L. Targeting the gut to treat multiple sclerosis. J Clin Invest. 2021;131(13). doi:10.1172/JCI143774.
   Web of Science ®Google Scholar
• Shahi SK, Freedman SN, Mangalam AK. Gut microbiome in multiple sclerosis: the players involved and the roles they play. Gut Microbes. 2017;8(6):607–615. doi:10.1080/19490976.2017.1349041.
   PubMed Web of Science ®Google Scholar
• Maglione A, Zuccala M, Tosi M, Clerico M, Rolla S. Host genetics and gut microbiome: perspectives for multiple sclerosis. Genes (Basel). 2021;12(8):1181. doi:10.3390/genes12081181.
   PubMed Web of Science ®Google Scholar
• Shahi SK, Ali S, Jaime CM, Guseva NV, Mangalam AK. HLA class II polymorphisms modulate gut microbiota and experimental autoimmune encephalomyelitis phenotype. Immunohorizons. 2021;5(8):627–646. doi:10.4049/immunohorizons.2100024.
   PubMedGoogle Scholar
• Montgomery TL, Künstner A, Kennedy JJ, Fang Q, Asarian L, Culp-Hill R, D’Alessandro A, Teuscher C, Busch H, Krementsov DN, et al. Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity. Proc Natl Acad Sci U S A. 2020;117(44):27516–27527. doi:10.1073/pnas.2002817117.
   PubMed Web of Science ®Google Scholar
• Wang J, Thingholm LB, Skiecevičienė J, Rausch P, Kummen M, Hov JR, Degenhardt F, Heinsen F-A, Rühlemann MC, Szymczak S, et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet. 2016;48(11):1396–1406. doi:10.1038/ng.3695.
   PubMed Web of Science ®Google Scholar
• Ghareghani M, Reiter RJ, Zibara K, Farhadi NL, Vitamin D. Melatonin, and gut microbiota act in concert to initiate multiple sclerosis: a New mechanistic pathway. Front Immunol. 2018;9:2484. doi:10.3389/fimmu.2018.02484.
   PubMed Web of Science ®Google Scholar
• Boziki MK, Kesidou E, Theotokis P, Mentis AFA, Karafoulidou E, Melnikov M, Sviridova A, Rogovski V, Boyko A, Grigoriadis N, et al. Microbiome in multiple sclerosis; where are we, what we know and do not know. Brain Sci. 2020;10(4):234. doi:10.3390/brainsci10040234.
   PubMed Web of Science ®Google Scholar
• Inojosa H, Proschmann U, Akgun K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Ther Adv Chronic Dis. 2022;13:20406223211063032. doi:10.1177/20406223211063032.
   Web of Science ®Google Scholar
• Weld-Blundell IV, Grech L, Learmonth YC, Marck CH. Lifestyle and complementary therapies in multiple sclerosis guidelines: systematic review. Acta Neurol Scand. 2022;145(4):379–392. doi:10.1111/ane.13574.
   PubMed Web of Science ®Google Scholar
• Rumah KR, Linden J, Fischetti VA, Vartanian T, Esteban FJ. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PloS One. 2013;8(10):e76359. doi:10.1371/journal.pone.0076359.
   PubMed Web of Science ®Google Scholar
• Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(40):10713–10718. doi:10.1073/pnas.1711235114.
   PubMed Web of Science ®Google Scholar
• Baum K, Rejmus R, Dorffel Y. Commensal gut flora in MS: spatial organization and composition. Mult Scler. 2015;21:458–159.
   Web of Science ®Google Scholar
• Levi I, Gurevich M, Perlman G, Magalashvili D, Menascu S, Bar N, Godneva A, Zahavi L, Chermon D, Kosower N, et al. Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis. Cell Rep Med. 2021;2(4):100246. doi:10.1016/j.xcrm.2021.100246.
   PubMedGoogle Scholar
• Swidsinski A, Dörffel Y, Loening-Baucke V, Gille C, Göktas Ö, Reißhauer A, Neuhaus J, Weylandt K-H, Guschin A, Bock M, et al. Reduced Mass and diversity of the colonic microbiome in patients with multiple sclerosis and their improvement with Ketogenic Diet. Front Microbiol. 2017;8:1141. doi:10.3389/fmicb.2017.01141.
   PubMed Web of Science ®Google Scholar
• Cosorich I, Dalla-Costa G, Sorini C, Ferrarese R, Messina MJ, Dolpady J, Radice E, Mariani A, Testoni PA, Canducci F, et al. High frequency of intestinal T H 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3(7):e1700492. doi:10.1126/sciadv.1700492.
   PubMed Web of Science ®Google Scholar
• Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim S-W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PloS One. 2015;10(9):e0137429. doi:10.1371/journal.pone.0137429.
   PubMed Web of Science ®Google Scholar
• Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, Venkatesan A, Fraser CM, Mowry EM. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. Journal Of Investigative Medicine. 2015;63(5):729–734. doi:10.1097/JIM.0000000000000192.
   PubMed Web of Science ®Google Scholar
• Ling Z, Cheng Y, Yan X, Shao L, Liu X, Zhou D, Zhang L, Yu K, Zhao L, et al. Alterations of the fecal microbiota in Chinese patients with multiple sclerosis. Front Immunol. 2020;11:590783. doi:10.3389/fimmu.2020.590783.
   PubMed Web of Science ®Google Scholar
• Storm-Larsen C, Myhr K-M, Farbu E, Midgard R, Nyquist K, Broch L, Berg-Hansen P, Buness A, Holm K, Ueland T, et al. Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial. Mult Scler J Exp Transl Clin. 2019;5(4):2055217319888767. doi:10.1177/2055217319888767.
   Google Scholar
• Ventura RE, Iizumi T, Battaglia T, Liu M, Perez-Perez GI, Herbert J, Blaser MJ. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course. Sci Rep. 2019;9(1):16396. doi:10.1038/s41598-019-52894-z.
   PubMed Web of Science ®Google Scholar
• Oezguen N, Yalcinkaya N, Kücükali CI, Dahdouli M, Hollister EB, Luna RA, Türkoglu R, Kürtüncü M, Eraksoy M, Savidge TC, et al. Microbiota stratification identifies disease-specific alterations in neuro-Behçet’s disease and multiple sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 121(6):58–66.
   PubMed Web of Science ®Google Scholar
• Saresella M, Marventano I, Barone M, La Rosa F, Piancone F, Mendozzi L, d’Arma A, Rossi V, Pugnetti L, Roda G, et al. Alterations in circulating fatty acid are associated with gut microbiota dysbiosis and inflammation in multiple sclerosis. Front Immunol. 2020;11:1390. doi:10.3389/fimmu.2020.01390.
   PubMed Web of Science ®Google Scholar
• Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017;114(40):10719–10724. doi:10.1073/pnas.1711233114.
   PubMed Web of Science ®Google Scholar
• Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasén C, Tauhid S, Chu R, et al. Gut microbiome in progressive multiple sclerosis. Ann Neurol. 2021;89(6):1195–1211. doi:10.1002/ana.26084.
   PubMed Web of Science ®Google Scholar
• Takewaki D, Suda W, Sato W, Takayasu L, Kumar N, Kimura K, Kaga N, Mizuno T, Miyake S, Hattori M, et al. Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117(36):22402–22412. doi:10.1073/pnas.2011703117.
   PubMed Web of Science ®Google Scholar
• Cekanaviciute E, Debelius, JW, Singh S, Runia T, Nelson C, Yoo B, Kanner R, Crabtree-Hartman E, Mazmanian S, Knight R et al. Gut dysbiosis is a feature of MS and it is characterized by bacteria able to regulate lymphocyte differentiation in vitro. Mult Scler. 2016;22(S3):58–59.
   Google Scholar
• Zeng Q, Gong J, Liu X, Chen C, Sun X, Li H, Zhou Y, Cui C, Wang Y, Yang Y, et al. Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis. Neurochem Int. 2019;129:104468. doi:10.1016/j.neuint.2019.104468.
   PubMed Web of Science ®Google Scholar
• Forbes JD, Chen C-Y, Knox NC, Marrie R-A, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G. A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist? Microbiome. 2018;6(1):221. doi:10.1186/s40168-018-0603-4.
   PubMed Web of Science ®Google Scholar
• Kozhieva M, Naumova N, Alikina T, Boyko A, Vlassov V, Kabilov MR. Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity. BMC Microbiol. 2019;19(1):309. doi:10.1186/s12866-019-1685-2.
   PubMed Web of Science ®Google Scholar
• Choileain SN, Kleinewietfeld M, Raddassi K, Hafler DA, Ruff WE, Longbrake EE. CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. J Transl Autoimmunity. 2020;3:100032. doi:10.1016/j.jtauto.2019.100032.
   PubMedGoogle Scholar
• Reynders T, Devolder L, Valles‐Colomer M, Van Remoortel A, Joossens M, De Keyser J, Nagels G, D’hooghe M, Raes J. Gut microbiome variation is associated to multiple sclerosis phenotypic subtypes. Ann Clin Transl Neurol. 2020;7(4):406–419. doi:10.1002/acn3.51004.
   PubMed Web of Science ®Google Scholar
• Zhou X, Singh S, Baumann R, Barba P, Landefeld J, Casaccia P, Sand IK, Xia Z, Weiner H, Chitnis T, et al. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. Mult Scler. 2021;27(3):366–379. doi:10.1177/1352458520924594.
   Web of Science ®Google Scholar
• Zhou X, Baumann R, Gao X, Mendoza M, Singh S, Katz Sand I, Xia Z, Cox LM, Chitnis T, Yoon H. iMSMS & consortium. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467–3486.e16. doi:10.1016/j.cell.2022.08.021.
   PubMed Web of Science ®Google Scholar
• Johanson DM 2nd, Goertz JE, Marin IA, Costello J, Overall CC, Gaultier A. Experimental autoimmune encephalomyelitis is associated with changes of the microbiota composition in the gastrointestinal tract. Science Reports. 2020;10(1):15183. doi:10.1038/s41598-020-72197-y.
   PubMed Web of Science ®Google Scholar
• Gandy KAO, Zhang J, Nagarkatti P, Nagarkatti M. The role of gut microbiota in shaping the relapse-remitting and chronic-progressive forms of multiple sclerosis in mouse models. Sci Rep. 2019;9(1):6923. doi:10.1038/s41598-019-43356-7.
   PubMedGoogle Scholar
• Moles L, Egimendia A, Osorio-Querejeta I, Iparraguirre L, Alberro A, Suárez J, Sepúlveda L, Castillo-Triviño T, Muñoz-Culla M, Ramos-Cabrer P, et al. Gut microbiota changes in experimental autoimmune encephalomyelitis and cuprizone mice models. ACS Chem Neurosci. 2021;12(5):893–905. doi:10.1021/acschemneuro.0c00695.
   PubMed Web of Science ®Google Scholar
• Colpitts SL, Kasper EJ, Keever A, Liljenberg C, Kirby T, Magori K, Kasper LH, Ochoa-Repáraz J. A bidirectional association between the gut microbiota and CNS disease in a biphasic murine model of multiple sclerosis. Gut Microbes. 2017;8(6):561–573. doi:10.1080/19490976.2017.1353843.
   PubMed Web of Science ®Google Scholar
• Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2011;Suppl 108(supplement_1):4615–4622. doi:10.1073/pnas.1000082107.
   Google Scholar
• Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Begum-Haque S, Dasgupta S, Kasper DL, Kasper LH. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide a expression. The Journal Of Immunology. 2010;185(7):4101–4108. doi:10.4049/jimmunol.1001443.
   PubMed Web of Science ®Google Scholar
• Telesford KM, Yan W, Ochoa-Reparaz J, Pant A, Kircher C, Christy MA, Begum-Haque S, Kasper DL, Kasper LH. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39 + Foxp3 + T cells and T reg function. Gut Microbes. 2015;6(4):234–242. doi:10.1080/19490976.2015.1056973.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Ukibe K, Matsubara Y, Hosoya T, Sakai F, Kon S, Arima Y, Murakami M, Nakagawa H, Miyazaki T, et al. Lactobacillus helveticus SBT2171 attenuates experimental autoimmune encephalomyelitis in mice. Front Microbiol. 2017;8:2596. doi:10.3389/fmicb.2017.02596.
   PubMed Web of Science ®Google Scholar
• Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PloS One. 2010;5(2):e9009. doi:10.1371/journal.pone.0009009.
   PubMed Web of Science ®Google Scholar
• He B, Hoang TK, Tian X, Taylor CM, Blanchard E, Luo M, Bhattacharjee MB, Freeborn J, Park S, Couturier J, et al. Lactobacillus reuteri reduces the severity of experimental autoimmune encephalomyelitis in mice by modulating gut microbiota. Front Immunol. 2019;10:385. doi:10.3389/fimmu.2019.00385.
   PubMed Web of Science ®Google Scholar
• Consonni A, Cordiglieri C, Rinaldi E, Marolda R, Ravanelli I, Guidesi E, Elli M, Mantegazza R, Baggi F. Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. Oncotarget. 2018;9(32):22269–22287. doi:10.18632/oncotarget.25170.
   PubMedGoogle Scholar
• Ezendam J, de Klerk A, Gremmer ER, van Loveren H. Effects of Bifidobacterium animalis administered during lactation on allergic and autoimmune responses in rodents. Clin Exp Immunol. 2008;154(3):424–431. doi:10.1111/j.1365-2249.2008.03788.x.
   PubMed Web of Science ®Google Scholar
• Kwon HK, Kim G-C, Kim Y, Hwang W, Jash A, Sahoo A, Kim J-E, Nam JH, Im S-H. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clinical Immunology. 2013;146(3):217–227. doi:10.1016/j.clim.2013.01.001.
   PubMed Web of Science ®Google Scholar
• Salehipour Z, Haghmorad D, Sankian M, Rastin M, Nosratabadi R, Soltan Dallal MM, Tabasi N, Khazaee M, Nasiraii LR, Mahmoudi M, et al. Bifidobacterium animalis in combination with human origin of Lactobacillus plantarum ameliorate neuroinflammation in experimental model of multiple sclerosis by altering CD4+ T cell subset balance. Biomed Pharmacother. 2017;95:1535–1548. doi:10.1016/j.biopha.2017.08.117.
   PubMed Web of Science ®Google Scholar
• Mangalam A, Shahi SK, Luckey D, Karau M, Marietta E, Luo N, Choung RS, Ju J, Sompallae R, Gibson-Corley K, et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 2017;20(6):1269–1277. doi:10.1016/j.celrep.2017.07.031.
   PubMed Web of Science ®Google Scholar
• Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, et al. Gut dysbiosis and neuroimmune responses to brain infection with Theiler’s murine encephalomyelitis virus. Sci Rep. 2017;7(1):44377. doi:10.1038/srep44377.
   PubMed Web of Science ®Google Scholar
• Omura S, Sato F, Park A-M, Fujita M, Khadka S, Nakamura Y, Katsuki A, Nishio K, Gavins FNE, Tsunoda I, et al. Bioinformatics analysis of gut microbiota and CNS transcriptome in virus-induced acute myelitis and chronic inflammatory demyelination; potential association of Distinct bacteria with CNS IgA upregulation. Front Immunol. 2020;11:1138. doi:10.3389/fimmu.2020.01138.
   PubMed Web of Science ®Google Scholar
• Wang X, Chang L, Wan X, Tan Y, Qu Y, Shan J, Yang Y, Ma L, Hashimoto K. (R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut–microbiota–brain axis. Neurobiology Of Disease. 2022;165:105635. doi:10.1016/j.nbd.2022.105635.
   PubMed Web of Science ®Google Scholar
• Wang X, Eguchi A, Yang Y, Chang L, Wan X, Shan J, Qu Y, Ma L, Mori C, Yang J, et al. Key role of the gut–microbiota–brain axis via the subdiaphragmatic vagus nerve in demyelination of the cuprizone-treated mouse brain. Neurobiol Dis. 2023;176:105951. doi:10.1016/j.nbd.2022.105951.
   PubMed Web of Science ®Google Scholar
• Liu S, Rezende RM, Moreira TG, Tankou SK, Cox LM, Wu M, Song A, Dhang FH, Wei Z, Costamagna G, et al. Oral administration of miR-30d from feces of MS patients suppresses MS-like symptoms in mice by expanding Akkermansia muciniphila. Cell Host & Microbe. 2019;26(6):779–794.e8. doi:10.1016/j.chom.2019.10.008.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Jörg S, Duscha A, Berg J, Manzel A, Waschbisch A, Hammer A, Lee D-H, May C, Wilck N, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity. 2015;43(4):817–829. doi:10.1016/j.immuni.2015.09.007.
   PubMed Web of Science ®Google Scholar
• Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl GI, Dawin E, Bader V, Haase S, Kaisler J, David C, et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell. 2020;180(6):1067–1080.e16. doi:10.1016/j.cell.2020.02.035.
   PubMed Web of Science ®Google Scholar
• Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, Korecka A, Bakocevic N, Ng LG, Kundu P, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158. doi:10.1126/scitranslmed.3009759.
   PubMed Web of Science ®Google Scholar
• Mossad O, Erny D. The microbiota–microglia axis in central nervous system disorders. Brain Pathology. 2020;30(6):1159–1177. doi:10.1111/bpa.12908.
   PubMed Web of Science ®Google Scholar
• Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6(1):28484. doi:10.1038/srep28484.
   PubMed Web of Science ®Google Scholar
• Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7(1):12015. doi:10.1038/ncomms12015.
   PubMed Web of Science ®Google Scholar
• Hughes LE, Bonell S, Natt RS, Wilson C, Tiwana H, Ebringer A, Cunningham P, Chamoun V, Thompson EJ, Croker J, et al. Antibody responses to Acinetobacter spp. And Pseudomonas aeruginosa in multiple sclerosis: prospects for diagnosis using the myelin-acinetobacter-neurofilament antibody index. Clin Diagn Lab Immunol. 2001;8(6):1181–1188. doi:10.1128/CDLI.8.6.1181-1188.2001.
   PubMedGoogle Scholar
• Farrokhi V, Nemati R, Nichols FC, Yao X, Anstadt E, Fujiwara M, Grady J, Wakefield D, Castro W, Donaldson J, et al. Bacterial lipodipeptide, lipid 654, is a microbiome-associated biomarker for multiple sclerosis. Clin & Trans Imm. 2013;2(11):e8. doi:10.1038/cti.2013.11.
   PubMedGoogle Scholar
• Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–118. doi:10.1016/j.cell.2005.05.007.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Lynch S, Waubant E, Aaen G, Belman A, et al. Gut microbiota composition and relapse risk in pediatric MS: a pilot study. J Neurol Sci. 2016;363:153–157. doi:10.1016/j.jns.2016.02.042.
   PubMed Web of Science ®Google Scholar
• Cady N, Peterson SR, Freedman SN, Mangalam AK. Beyond metabolism: the complex interplay between dietary phytoestrogens, gut bacteria, and cells of nervous and immune systems. Front Neurol. 2020;11:150. doi:10.3389/fneur.2020.00150.
   PubMed Web of Science ®Google Scholar
• Freedman SN, Shahi SK, Mangalam AK. The “gut feeling”: breaking down the role of gut microbiome in multiple sclerosis. Neurotherapeutics. 2018;15(1):109–125. doi:10.1007/s13311-017-0588-x.
   PubMed Web of Science ®Google Scholar
• Cocchi M, Mondo E, Romeo M, Traina G. The inflammatory conspiracy in multiple sclerosis: a crossroads of clues and insights through mast cells, platelets, inflammation, gut microbiota, mood disorders and stem cells. Int J Mol Sci. 2022;23(6):3253. doi:10.3390/ijms23063253.
   PubMed Web of Science ®Google Scholar
• Garabatos N, Santamaria P. Gut microbial antigenic mimicry in autoimmunity. Front Immunol. 2022;13:873607. doi:10.3389/fimmu.2022.873607.
   PubMed Web of Science ®Google Scholar
• Elsayed NS, Aston P, Bayanagari VR, Shukla SK. The gut microbiome molecular mimicry piece in the multiple sclerosis puzzle. Front Immunol. 2022;13:972160. doi:10.3389/fimmu.2022.972160.
   PubMedGoogle Scholar
• Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312–11319. doi:10.1074/jbc.M211609200.
   PubMed Web of Science ®Google Scholar
• Liu J, Li H, Gong T, Chen W, Mao S, Kong Y, Yu J, Sun J. Anti-neuroinflammatory effect of short-chain fatty acid acetate against Alzheimer’s disease via upregulating GPR41 and inhibiting ERK/JNK/NF-κB. J Agric Food Chem. 2020;68(27):7152–7161. doi:10.1021/acs.jafc.0c02807.
   PubMed Web of Science ®Google Scholar
• Chevalier AC, Rosenberger TA. Increasing acetyl-CoA metabolism attenuates injury and alters spinal cord lipid content in mice subjected to experimental autoimmune encephalomyelitis. J Neurochem. 2017;141(5):721–737. doi:10.1111/jnc.14032.
   PubMed Web of Science ®Google Scholar
• Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis. Sci. 2013;341(6145):569–573. doi:10.1126/science.1241165.
   PubMed Web of Science ®Google Scholar
• Hoyles L, Snelling T, Umlai U-K, Nicholson JK, Carding SR, Glen RC, McArthur S. Microbiome–host systems interactions: protective effects of propionate upon the blood–brain barrier. Microbiome. 2018;6(1). doi:10.1186/s40168-018-0439-y.
   Google Scholar
• Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–450. doi:10.1038/nature12721.
   PubMed Web of Science ®Google Scholar
• Kespohl M, Vachharajani N, Luu M, Harb H, Pautz S, Wolff S, Sillner N, Walker A, Schmitt-Kopplin P, Boettger T, et al. The microbial metabolite butyrate induces expression of Th1-associated factors in CD4(+) T cells. Front Immunol. 2017;8:1036. doi:10.3389/fimmu.2017.01036.
   PubMed Web of Science ®Google Scholar
• Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014;111(6):2247–2252. doi:10.1073/pnas.1322269111.
   PubMed Web of Science ®Google Scholar
• Chen T, Noto D, Hoshino Y, Mizuno M, Miyake S. Butyrate suppresses demyelination and enhances remyelination. J Neuroinflammation. 2019;16(1):165. doi:10.1186/s12974-019-1552-y.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455. doi:10.1038/nature12726.
   PubMed Web of Science ®Google Scholar
• Luu M, Pautz S, Kohl V, Singh R, Romero R, Lucas S, Hofmann J, Raifer H, Vachharajani N, Carrascosa LC, et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat Commun. 2019;10(1):760. doi:10.1038/s41467-019-08711-2.
   PubMedGoogle Scholar
• Park J, Wang Q, Wu Q, Mao-Draayer Y, Kim CH. Bidirectional regulatory potentials of short-chain fatty acids and their G-protein-coupled receptors in autoimmune neuroinflammation. Sci Rep. 2019;9(1):8837. doi:10.1038/s41598-019-45311-y.
   PubMedGoogle Scholar
• Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965–977. doi:10.1038/nn.4030.
   PubMed Web of Science ®Google Scholar
• Wenzel TJ, Gates EJ, Ranger AL, Klegeris A. Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells. Mol Cell Neurosci. 2020;105:103493. doi:10.1016/j.mcn.2020.103493.
   PubMed Web of Science ®Google Scholar
• Sundaram TS, Giromini C, Rebucci R, Baldi A. Omega-3 Polyunsaturated fatty acids counteract inflammatory and oxidative damage of non-transformed porcine enterocytes. Anim (Basel). 2020;10(6):956. doi:10.3390/ani10060956.
   PubMedGoogle Scholar
• Denys A, Hichami A, Khan NA. N-3 PUFAs modulate T-cell activation via protein kinase C-α and -ε and the NF-κB signaling pathway. J Lipid Res. 2005;46(4):752–758. doi:10.1194/jlr.M400444-JLR200.
   PubMed Web of Science ®Google Scholar
• Djuricic I, Calder PC. Beneficial outcomes of omega-6 and omega-3 Polyunsaturated fatty acids on human health: an update for 2021. Nutrients. 2021;13(7):2421. doi:10.3390/nu13072421.
   PubMed Web of Science ®Google Scholar
• Fu Y, Wang Y, Gao H, Li D, Jiang R, Ge L, Tong C, Xu K. Associations among dietary omega-3 Polyunsaturated fatty acids, the gut microbiota, and intestinal immunity. Mediators Of Inflammation. 2021;2021:1–11. doi:10.1155/2021/8879227.
   Web of Science ®Google Scholar
• Montgomery TL, Eckstrom K, Lile KH, Caldwell S, Heney ER, Lahue KG, D’Alessandro A, Wargo MJ, Krementsov DN. Lactobacillus reuteri tryptophan metabolism promotes host susceptibility to CNS autoimmunity. Microbiome. 2022;10(1):198. doi:10.1186/s40168-022-01408-7.
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Borucki DM, Garcia Sanchez MI, Mazzola MA, Hemond CC, Regev K, Paul A, Kivisäkk P, Bakshi R, Izquierdo G, et al. Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e359. doi:10.1212/NXI.0000000000000359.
   PubMed Web of Science ®Google Scholar
• Sonner JK, Keil M, Falk-Paulsen M, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, et al. Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. Nat Commun. 2019;10(1):4877. doi:10.1038/s41467-019-12776-4.
   PubMedGoogle Scholar
• Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, Haase S, Mähler A, Balogh A, Markó L, et al. Salt-responsive gut commensal modulates T(H)17 axis and disease. Nature. 2017;551(7682):585–589. doi:10.1038/nature24628.
   PubMed Web of Science ®Google Scholar
• Zelante T, Iannitti R, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D’Angelo C, Massi-Benedetti C, Fallarino F, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–385. doi:10.1016/j.immuni.2013.08.003.
   PubMed Web of Science ®Google Scholar
• Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet A, Qiu Z, Maher L, Redinbo M, Phillips R, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity. 2014;41(2):296–310. doi:10.1016/j.immuni.2014.06.014.
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao C-C, Patel B, Yan R, Blain M, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22(6):586–597. doi:10.1038/nm.4106.
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao C-C, Ardura-Fabregat A, de Lima KA, Gutiérrez-Vázquez C, Hewson P, Staszewski O, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557(7707):724–728. doi:10.1038/s41586-018-0119-x.
   PubMed Web of Science ®Google Scholar
• Owe-Young R, Webster NL, Mukhtar M, Pomerantz RJ, Smythe G, Walker D, Armati PJ, Crowe SM, Brew BJ. Kynurenine pathway metabolism in human blood–brain–barrier cells: implications for immune tolerance & neurotoxicity. J Neurochem. 2008;105(4):1346–1357. doi:10.1111/j.1471-4159.2008.05241.x.
   PubMed Web of Science ®Google Scholar
• Lim CK, Bilgin A, Lovejoy DB, Tan V, Bustamante S, Taylor BV, Bessede A, Brew BJ, Guillemin GJ. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep-Uk. 2017;7(1). doi:10.1038/srep41473.
   Google Scholar
• Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49(1):15–23. doi:10.1002/glia.20090.
   PubMed Web of Science ®Google Scholar
• Rothhammer V, Kenison JE, Li Z, Tjon E, Takenaka MC, Chao C-C, Alves de Lima K, Borucki DM, Kaye J, Quintana FJ, et al. Aryl hydrocarbon receptor activation in astrocytes by laquinimod ameliorates autoimmune inflammation in the CNS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e946. doi:10.1212/NXI.0000000000000946.
   PubMed Web of Science ®Google Scholar
• Haase S, Haghikia A, Wilck N, Muller DN, Linker RA. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology. 2018;154(2):230–238. doi:10.1111/imm.12933.
   PubMed Web of Science ®Google Scholar
• Calvo-Barreiro L, Eixarch H, Ponce-Alonso M, Castillo M, Lebrón-Galán R, Mestre L, Guaza C, Clemente D, Del Campo R, Montalban X, et al. A commercial probiotic induces tolerogenic and reduces pathogenic responses in experimental autoimmune encephalomyelitis. Cells. 2020;9(4):906. doi:10.3390/cells9040906.
   PubMed Web of Science ®Google Scholar
• San Hernandez AM, Singh C, Valero DJ, Nisar J, Trujillo Ramirez JI, Kothari KK, Isola S, Gordon DK. Multiple sclerosis and serotonin: potential therapeutic applications. Cureus. 2020;12:e11293. doi:10.7759/cureus.11293.
   PubMed Web of Science ®Google Scholar
• Wagner A, Wang C, Fessler J, DeTomaso D, Avila-Pacheco J, Kaminski J, Zaghouani S, Christian E, Thakore P, Schellhaass B, et al. Metabolic modeling of single Th17 cells reveals regulators of autoimmunity. Cell. 2021;184(16):4168–4185.e21. doi:10.1016/j.cell.2021.05.045.
   PubMed Web of Science ®Google Scholar
• Carriche GM, Almeida L, Stüve P, Velasquez L, Dhillon-LaBrooy A, Roy U, Lindenberg M, Strowig T, Plaza-Sirvent C, Schmitz I, et al. Regulating T-cell differentiation through the polyamine spermidine. J Allergy Clin Immun. 2021;147(1):335–348.e11. doi:10.1016/j.jaci.2020.04.037.
   PubMed Web of Science ®Google Scholar
• Yang Q, Zheng C, Cao J, Cao G, Shou P, Lin L, Velletri T, Jiang M, Chen Q, Han Y, et al. Spermidine alleviates experimental autoimmune encephalomyelitis through inducing inhibitory macrophages. Cell Death Differ. 2016;23(11):1850–1861. doi:10.1038/cdd.2016.71.
   PubMed Web of Science ®Google Scholar
• Guo X, Harada C, Namekata K, Kimura A, Mitamura Y, Yoshida H, Matsumoto Y, Harada T. Spermidine alleviates severity of murine experimental autoimmune encephalomyelitis. Invest Ophthalmol Vis Sci. 2011;52(5):2696–2703. doi:10.1167/iovs.10-6015.
   PubMed Web of Science ®Google Scholar
• Soda K, Kano Y, Nakamura T, Kasono K, Kawakami M, Konishi F. Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. The Journal Of Immunology. 2005;175(1):237–245. doi:10.4049/jimmunol.175.1.237.
   PubMed Web of Science ®Google Scholar
• Zhang S, Al-Maghout T, Cao H, Pelzl L, Salker MS, Veldhoen M, Cheng A, Lang F, Singh Y. Gut bacterial metabolite Urolithin a (UA) mitigates Ca(2+) entry in T cells by regulating miR-10a-5p. Front Immunol. 2019;10:1737. doi:10.3389/fimmu.2019.01737.
   PubMed Web of Science ®Google Scholar
• Shen PX, Li X, Deng S-Y, Zhao L, Zhang Y-Y, Deng X, Han B, Yu J, Li Y, Wang Z-Z, et al. Urolithin a ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor. EBioMedicine. 2021;64:103227. doi:10.1016/j.ebiom.2021.103227.
   PubMed Web of Science ®Google Scholar
• Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat Commun. 2019;10(1). doi:10.1038/s41467-018-07859-7.
   Google Scholar
• Gong Z, Huang J, Xu B, Ou Z, Zhang L, Lin X, Ye X, Kong X, Long D, Sun X, et al. Urolithin a attenuates memory impairment and neuroinflammation in APP/PS1 mice. J Neuroinflammation. 2019;16(1):62. doi:10.1186/s12974-019-1450-3.
   PubMedGoogle Scholar
• DaSilva NA, Nahar PP, Ma H, Eid A, Wei Z, Meschwitz S, Zawia NH, Slitt AL, Seeram NP. Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutritional Neuroscience. 2019;22(3):185–195. doi:10.1080/1028415X.2017.1360558.
   PubMed Web of Science ®Google Scholar
• Busto R, Serna J, Perianes-Cachero A, Quintana-Portillo R, García-Seisdedos D, Canfrán-Duque A, Paino CL, Lerma M, Casado ME, Martín-Hidalgo A, et al. Ellagic acid protects from myelin-associated sphingolipid loss in experimental autoimmune encephalomyelitis. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(9):958–967. doi:10.1016/j.bbalip.2018.05.009.
   PubMed Web of Science ®Google Scholar
• Chen P, Chen FC, Lei JX, Wang GH, Zhou BH. The gut microbiota metabolite Urolithin B improves cognitive deficits by Inhibiting Cyt C-Mediated apoptosis and promoting the survival of neurons through the PI3K pathway in aging mice. Front Pharmacol. 2021;12:768097. doi:10.3389/fphar.2021.768097.
   PubMed Web of Science ®Google Scholar
• Castillo-Alvarez F, Perez-Matute P, Oteo JA, Marzo-Sola ME. The influence of interferon β-1b on gut microbiota composition in patients with multiple sclerosis. Neurología (English Ed). 2021;36(7):495–503. doi:10.1016/j.nrleng.2020.05.006.
   PubMed Web of Science ®Google Scholar
• Katz Sand I, Zhu Y, Ntranos A, Clemente JC, Cekanaviciute E, Brandstadter R, Crabtree-Hartman E, Singh S, Bencosme Y, Debelius J, et al. Disease-modifying therapies alter gut microbial composition in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e517. doi:10.1212/NXI.0000000000000517.
   PubMed Web of Science ®Google Scholar
• Abdurasulova IN, Tarasova EA, Nikiforova IG, Il’ves AG, Ivashkova EV, Matsulevich AV, Tatarinov AE, Shangina LV, Ermolenko EI, Klimenko VM, et al. The intestinal microbiota composition in patients with multiple sclerosis receiving different disease-modifying therapies DMT. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8):62–69. doi:10.17116/jnevro201811808262.
   PubMedGoogle Scholar
• Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S, Waubant E. Gut microbiota in early pediatric multiple sclerosis: a case−control study. Euro J Of Neurology. 2016;23(8):1308–1321. doi:10.1111/ene.13026.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil SS, Waubant E, et al. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol. 2016;16(1):182. doi:10.1186/s12883-016-0703-3.
   PubMed Web of Science ®Google Scholar
• Shahi SK, Freedman SN, Murra AC, Zarei K, Sompallae R, Gibson-Corley KN, Karandikar NJ, Murray JA, Mangalam AK. Prevotella histicola, a human gut commensal, is as potent as COPAXONE® in an animal model of multiple sclerosis. Front Immunol. 2019;10:462. doi:10.3389/fimmu.2019.00462.
   PubMed Web of Science ®Google Scholar
• Rumah KR, Vartanian TK, Fischetti VA. Oral multiple sclerosis drugs inhibit the in vitro growth of epsilon toxin producing gut bacterium, Clostridium perfringens. Front Cell Infect Microbiol. 2017;7:11. doi:10.3389/fcimb.2017.00011.
   PubMed Web of Science ®Google Scholar
• Li QR, Wang CY, Tang C, He Q, Li N, Li JS. Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment. Am J Transplant. 2013;13(4):899–910. doi:10.1111/ajt.12148.
   PubMed Web of Science ®Google Scholar
• Diebold M, Meola M, Purushothaman S, Siewert LK, Pössnecker E, Roloff T, Lindberg RL, Kuhle J, Kappos L, Derfuss T, et al. Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis. Gut Microbes. 2022;14(1):2147055. doi:10.1080/19490976.2022.2147055.
   PubMed Web of Science ®Google Scholar
• Dehghani F, Abdollahi S, Shidfar F, Clark CCT, Soltani S. Probiotics supplementation and brain-derived neurotrophic factor (BDNF): a systematic review and meta-analysis of randomized controlled trials. Nutr Neurosci. 2022;1–11. doi:10.1080/1028415X.2022.2110664.
   Web of Science ®Google Scholar
• Valizadeh S, Majdi Seghinsara A, Maleki Chollou K, Bahadori A, Abbaszadeh S, Taghdir M, Behniafar H, Riahi SM. The efficacy of probiotics in experimental autoimmune encephalomyelitis (an animal model for MS): a systematic review and meta-analysis. Lett Appl Microbiol. 2021;73(4):408–417. doi:10.1111/lam.13543.
   PubMed Web of Science ®Google Scholar
• Kap YS, Bus-Spoor C, van Driel N, Dubbelaar ML, Grit C, Kooistra SM, Fagrouch ZC, Verschoor EJ, Bauer J, Eggen BJL, et al. Targeted diet modification reduces multiple sclerosis–like disease in adult marmoset monkeys from an outbred colony. J Immunol. 2018;201(11):3229–3243. doi:10.4049/jimmunol.1800822.
   PubMed Web of Science ®Google Scholar
• Mestre L, Carrillo-Salinas FJ, Feliú A, Mecha M, Alonso G, Espejo C, Calvo-Barreiro L, Luque-García JL, Estevez H, Villar LM, et al. How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. Gut Microbes. 2020;12(1):1813532. doi:10.1080/19490976.2020.1813532.
   PubMed Web of Science ®Google Scholar
• Delgado S, Sanchez B, Margolles A, Ruas-Madiedo P, Ruiz L. Molecules produced by probiotics and intestinal microorganisms with immunomodulatory activity. Nutrients. 2020;12(2):391. doi:10.3390/nu12020391.
   PubMed Web of Science ®Google Scholar
• Moravejolahkami AR, Paknahad Z, Chitsaz A. Dietary intake of energy and fiber in MS patients; an approach to prebiotics role. Nutr Food Sci. 2019;49(6):1039–1050. doi:10.1108/NFS-01-2019-0001.
   Web of Science ®Google Scholar
• Mirashrafi S, Hejazi Taghanaki SZ, Sarlak F, Moravejolahkami AR, Hojjati Kermani MA, Haratian M. Effect of probiotics supplementation on disease progression, depression, general health, and anthropometric measurements in relapsing-remitting multiple sclerosis patients: a systematic review and meta-analysis of clinical trials. Int J Clin Pract. 2021;75(11):e14724. doi:10.1111/ijcp.14724.
   PubMed Web of Science ®Google Scholar
• Jiang J, Chu C, Wu C, Wang C, Zhang C, Li T, Zhai Q, Yu L, Tian F, Chen W, et al. Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials. Food Funct. 2021;12(6):2354–2377. doi:10.1039/D0FO03203D.
   PubMed Web of Science ®Google Scholar
• Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, Jafari P, Asemi Z. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36(5):1245–1249. doi:10.1016/j.clnu.2016.08.015.
   PubMed Web of Science ®Google Scholar
• Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Hrishikesh L, Gandhi R, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018;83(6):1147–1161. doi:10.1002/ana.25244.
   PubMed Web of Science ®Google Scholar
• Zeraati M, Enayati M, Kafami L, Shahidi SH, Salari AA. Gut microbiota depletion from early adolescence alters adult immunological and neurobehavioral responses in a mouse model of multiple sclerosis. Neuropharmacology. 2019;157:107685. doi:10.1016/j.neuropharm.2019.107685.
   PubMed Web of Science ®Google Scholar
• Bianchimano P, Britton GJ, Wallach DS, Smith EM, Cox LM, Liu S, Iwanowski K, Weiner HL, Faith JJ, Clemente JC, et al. Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis. Microbiome. 2022;10(1):174. doi:10.1186/s40168-022-01364-2.
   PubMed Web of Science ®Google Scholar
• Chen H, Ma X, Liu Y, Ma L, Chen Z, Lin X, Si L, Ma X, Chen X. Gut microbiota interventions with Clostridium butyricum and norfloxacin modulate immune response in experimental autoimmune encephalomyelitis mice. Front Immunol. 2019;10:1662. doi:10.3389/fimmu.2019.01662.
   PubMed Web of Science ®Google Scholar
• Yokote H, Miyake S, Croxford JL, Oki S, Mizusawa H, Yamamura T. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. The American Journal Of Pathology. 2008;173(6):1714–1723. doi:10.2353/ajpath.2008.080622.
   PubMed Web of Science ®Google Scholar
• Miyauchi E, Kim S-W, Suda W, Kawasumi M, Onawa S, Taguchi-Atarashi N, Morita H, Taylor TD, Hattori M, Ohno H, et al. Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature. 2020;585(7823):102–106. doi:10.1038/s41586-020-2634-9.
   PubMed Web of Science ®Google Scholar
• McMurran CE, Guzman de la Fuente A, Penalva R, Ben Menachem-Zidon O, Dombrowski Y, Falconer J, Gonzalez GA, Zhao C, Krause FN, Young AMH, et al. The microbiota regulates murine inflammatory responses to toxin-induced CNS demyelination but has minimal impact on remyelination. Proc Natl Acad Sci U S A. 2019;116(50):25311–25321. doi:10.1073/pnas.1905787116.
   PubMed Web of Science ®Google Scholar
• Suleiman L, Waubant E, Aaen G, Belman A, Benson L, Candee M, Chitnis T, Gorman M, Goyal M, Greenberg B, et al. Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Mult Scler Relat Disord. 2018;22:103–107. doi:10.1016/j.msard.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Baldin E, Zenesini C, Antonazzo IC, Bartolomei I, Caniatti L, Costa M, Curti E, Ferraro D, Foschi M, Granella F, et al. Antibiotic use and risk of multiple sclerosis: a nested case-control study in Emilia-Romagna region, Italy. Neuroepidemiology. 2021;55(3):224–231. doi:10.1159/000515682.
   PubMed Web of Science ®Google Scholar
• Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW. Glatiramer acetate in combination with minocycline in patients with relapsing—remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009;15(10):1183–1194. doi:10.1177/1352458509106779.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, et al. Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study. Eur J Neurol. 2016;23(5):861–870. doi:10.1111/ene.12953.
   PubMed Web of Science ®Google Scholar
• Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC. Dietary interventions for multiple sclerosis-related outcomes. Cochrane Database Syst Rev. 2020;2020(5):CD004192. doi:10.1002/14651858.CD004192.pub4.
   Google Scholar
• Sanchez JMS, DePaula-Silva AB, Libbey JE, Fujinami RS. Role of diet in regulating the gut microbiota and multiple sclerosis. Clin Immunol. 2022;235:108379. doi:10.1016/j.clim.2020.108379.
   PubMed Web of Science ®Google Scholar
• Valburg C, Sonti A, Stern JN, Najjar S, Harel A. Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: a comprehensive review. Mult Scler. 2021;27(4):494–502. doi:10.1177/1352458520923955.
   PubMed Web of Science ®Google Scholar
• Bhargava P, Cassard S, Steele SU, Azevedo C, Pelletier D, Sugar EA, Waubant E, Mowry EM. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemporary Clinical Trials. 2014;39(2):288–293. doi:10.1016/j.cct.2014.10.004.
   PubMed Web of Science ®Google Scholar
• Rosjo E, Steffensen LH, Jørgensen L, Lindstrøm JC, Šaltytė Benth J, Michelsen AE, Aukrust P, Ueland T, Kampman MT, Torkildsen Ø, et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. J Neurol. 2015;262(12):2713–2721. doi:10.1007/s00415-015-7902-5.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, Munger KL, Köchert K, Arnason BGW, Comi G, Cook S, Goodin DS, Filippi M, Hartung H-P, Jeffery DR, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol. 2015;72(12):1458–1465. doi:10.1001/jamaneurol.2015.2742.
   PubMed Web of Science ®Google Scholar
• Shieh A, Lee, SM, Lagishetty V, Gottleib C, Jacobs, JP, Adams, JS. Pilot trial of vitamin D3 and calcifediol in healthy vitamin D deficient adults: does it change the fecal microbiome? J Clin Endocrinol Metab. 2021;106(12):3464–3476. doi:10.1210/clinem/dgab573.
   PubMed Web of Science ®Google Scholar
• Naderpoor N, Mousa A, Fernanda Gomez Arango L, Barrett HL, Dekker Nitert M, de Courten B. Effect of vitamin D supplementation on faecal microbiota: a randomised clinical trial. Nutrients. 2019;11(12):2888. doi:10.3390/nu11122888.
   PubMed Web of Science ®Google Scholar
• Enam F, Mansell TJ. Prebiotics: tools to manipulate the gut microbiome and metabolome. J Ind Microbiol Biotechnol. 2019;46(9–10):1445–1459. doi:10.1007/s10295-019-02203-4.
   PubMed Web of Science ®Google Scholar
• Berer K, Martínez I, Walker A, Kunkel B, Schmitt-Kopplin P, Walter J, Krishnamoorthy G. Dietary non-fermentable fiber prevents autoimmune neurological disease by changing gut metabolic and immune status. Sci Rep. 2018;8(1):10431. doi:10.1038/s41598-018-28839-3.
   PubMedGoogle Scholar
• Moravejolahkami AR, Paknahad Z, Chitsaz A. Dietary intake of energy and fiber in MS patients; an approach to prebiotics role. Nutr Food Sci. 2019;49(6):1039–1050. doi:10.1108/NFS-01-2019-0001.
   Web of Science ®Google Scholar
• Calvo-Barreiro L, Eixarch H, Cornejo T, Costa C, Castillo M, Mestre L, Guaza C, Martínez-Cuesta MDC, Tanoue T, Honda K, et al. Selected Clostridia strains from the human microbiota and their metabolite, butyrate, improve experimental autoimmune encephalomyelitis. Neurotherapeutics. 2021;18(2):920–937. doi:10.1007/s13311-021-01016-7.
   PubMed Web of Science ®Google Scholar
• Di Biase A, Salvati S, Di Benedetto R, Attorri L, Martinelli A, Malchiodi F. Eicosapentaenoic acid pre-treatment reduces biochemical changes induced in total brain and myelin of weanling wistar rats by cuprizone feeding. Prostaglandins, Leukotrienes And Essential Fatty Acids. 2014;90(4):99–104. doi:10.1016/j.plefa.2013.11.004.
   PubMed Web of Science ®Google Scholar
• Torkildsen Ø, Brunborg LA, Thorsen F, Mørk SJ, Stangel M, Myhr K-M, Bø L. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol. 2009;215(1):160–166. doi:10.1016/j.expneurol.2008.09.026.
   PubMed Web of Science ®Google Scholar
• Fleck AK, Hucke S, Teipel F, Eschborn M, Janoschka C, Liebmann M, Wami H, Korn L, Pickert G, Hartwig M, et al. Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity. Brain. 2021;144(4):1152–1166. doi:10.1093/brain/awab040.
   PubMedGoogle Scholar
• Dong TA, Sandesara PB, Dhindsa DS, Mehta A, Arneson LC, Dollar AL, Taub PR, Sperling LS. Intermittent fasting: a heart healthy dietary pattern? The American Journal Of Medicine. 2020;133(8):901–907. doi:10.1016/j.amjmed.2020.03.030.
   PubMed Web of Science ®Google Scholar
• Catenacci VA, Pan Z, Ostendorf D, Brannon S, Gozansky WS, Mattson MP, Martin B, MacLean PS, Melanson EL, Troy Donahoo W, et al. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Obesity (Silver Spring). 2016;24(9):1874–1883. doi:10.1002/oby.21581.
   PubMed Web of Science ®Google Scholar
• Duenas M, Muñoz-González I, Cueva C, Jiménez-Girón A, Sánchez-Patán F, Santos-Buelga C, Moreno-Arribas MV, Bartolomé B. A survey of modulation of gut microbiota by dietary polyphenols. BioMed Research International. 2015;2015:1–15. doi:10.1155/2015/850902.
   Web of Science ®Google Scholar
• Ginwala R, McTish E, Raman C, Singh N, Nagarkatti M, Nagarkatti P, Sagar D, Jain P, Khan ZK. Apigenin, a natural flavonoid, attenuates EAE severity through the modulation of dendritic cell and other immune cell functions. J Neuroimmune Pharmacol. 2016;11(1):36–47. doi:10.1007/s11481-015-9617-x.
   PubMed Web of Science ®Google Scholar
• Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel P-M, Infante-Duarte C, Brocke S, Zipp F. Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB inhibition and exerts Neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004;173(9):5794–5800. doi:10.4049/jimmunol.173.9.5794.
   PubMed Web of Science ®Google Scholar
• Haghmorad D, Mahmoudi, MB, Salehipour Z, Jalayer Z, Rastin M, Kokhaei P, Mahmoudi M. Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis. J Neuroimmunol. 2017;302:23–33. doi:10.1016/j.jneuroim.2016.11.009.
   PubMed Web of Science ®Google Scholar
• Verbeek R, van Tol EA, van Noort JM. Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. Biochem Pharmacol. 2005;70(2):220–228. doi:10.1016/j.bcp.2005.04.041.
   PubMed Web of Science ®Google Scholar
• Sato F, Martinez NE, Shahid M, Rose JW, Carlson NG, Tsunoda I. Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. The American Journal Of Pathology. 2013;183(5):1390–1396. doi:10.1016/j.ajpath.2013.07.006.
   PubMed Web of Science ®Google Scholar
• Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen AA. Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study. Mol Neurobiol. 2017;54(5):3219–3229. doi:10.1007/s12035-016-9891-5.
   PubMed Web of Science ®Google Scholar
• Dolati S, Babaloo Z, Ayromlou H, Ahmadi M, Rikhtegar R, Rostamzadeh D, Roshangar L, Nouri M, Mehdizadeh A, Younesi V, et al. Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis. J Neuroimmunol. 2019;327:15–21. doi:10.1016/j.jneuroim.2019.01.007.
   PubMed Web of Science ®Google Scholar
• Wang C, Huang Z, Yu K, Ding R, Ye K, Dai C, Xu X, Zhou G, Li C. High-salt diet has a certain impact on protein Digestion and gut microbiota: a sequencing and proteome combined study. Front Microbiol. 2017;8:1838. doi:10.3389/fmicb.2017.01838.
   PubMed Web of Science ®Google Scholar
• Ferguson JF, Aden LA, Barbaro NR, Van Beusecum JP, Xiao L, Simons AJ, Warden C, Pasic L, Himmel LE, Washington MK, et al. High dietary salt–induced DC activation underlies microbial dysbiosis-associated hypertension. JCI Insight. 2019;5(13). doi:10.1172/jci.insight.126241.
   Google Scholar
• Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, Deng S, Herold KC, Kuchroo VK, Kleinewietfeld M, et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J Clin Invest. 2015;125(11):4212–4222. doi:10.1172/JCI81151.
   PubMed Web of Science ®Google Scholar
• Haase S, Wilck N, Haghikia A, Gold R, Mueller DN, Linker RA. The role of the gut microbiota and microbial metabolites in neuroinflammation. Eur J Immunol. 2020;50(12):1863–1870. doi:10.1002/eji.201847807.
   PubMed Web of Science ®Google Scholar
• Farez MF, Fiol MP, Gaitan MI, Quintana FJ, Correale J. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):26–31. doi:10.1136/jnnp-2014-307928.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, Munger KL, Hartung H-P, Freedman MS, Montalbán X, Edan G, Wicklein E-M, Radue E-W, Kappos L, Pohl C, et al. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017;82(1):20–29. doi:10.1002/ana.24965.
   PubMed Web of Science ®Google Scholar
• McDonald J, Graves J, Waldman A, Lotze T, Schreiner T, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema J-M, et al. A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Mult Scler Relat Disord. 2016;6:87–92. doi:10.1016/j.msard.2016.02.011.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh B, Graves J, Casper TC, Lulu S, Waldman A, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema J-M, et al. Dietary salt intake and time to relapse in paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(12):1350–1353. doi:10.1136/jnnp-2016-313410.
   PubMed Web of Science ®Google Scholar
• Phillips MCL. Fasting as a Therapy in neurological disease. Nutrients. 2019;11(10):2501. doi:10.3390/nu11102501.
   PubMed Web of Science ®Google Scholar
• Storoni M, Plant GT. The therapeutic potential of the ketogenic diet in treating progressive multiple sclerosis. Mult Scler Int. 2015;2015:681289. doi:10.1155/2015/681289.
   PubMed Web of Science ®Google Scholar
• Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, Suarez J, Michalsen A, Cross A, Morgan T, et al. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 2016;15(10):2136–2146. doi:10.1016/j.celrep.2016.05.009.
   PubMed Web of Science ®Google Scholar
• Razeghi Jahromi S, Ghaemi A, Alizadeh A, Sabetghadam F, Moradi Tabriz H, Togha M. Effects of intermittent fasting on experimental Autoimune encephalomyelitis in C57BL/6 mice. Iran J Allergy Asthma Immunol. 2016;15:212–219.
   PubMed Web of Science ®Google Scholar
• Bai M, Wang Y, Han R, Xu L, Huang M, Zhao J, Lin Y, Song S, Chen Y. Intermittent caloric restriction with a modified fasting-mimicking diet ameliorates autoimmunity and promotes recovery in a mouse model of multiple sclerosis. J Nutr Biochem. 2021;87:108493. doi:10.1016/j.jnutbio.2020.108493.
   PubMed Web of Science ®Google Scholar
• Cignarella F, Cantoni C, Ghezzi L, Salter A, Dorsett Y, Chen L, Phillips D, Weinstock GM, Fontana L, Cross AH, et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 2018;27(6):1222–1235.e6. doi:10.1016/j.cmet.2018.05.006.
   PubMed Web of Science ®Google Scholar
• Bahr LS, Bock M, Liebscher D, Bellmann-Strobl J, Franz L, Prüß A, Schumann D, Piper SK, Kessler CS, Steckhan N, et al. Ketogenic diet and fasting diet as nutritional approaches in multiple sclerosis (NAMS): protocol of a randomized controlled study. Trials. 2020;21(1). doi:10.1186/s13063-019-3928-9.
   Google Scholar
• Cantoni C, Lin Q, Dorsett Y, Ghezzi L, Liu Z, Pan Y, Chen K, Han Y, Li Z, Xiao H, et al. Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine. 2022;76:103798. doi:10.1016/j.ebiom.2021.103798.
   PubMed Web of Science ®Google Scholar
• Saresella M, Mendozzi L, Rossi V, Mazzali F, Piancone F, LaRosa F, Marventano I, Caputo D, Felis GE, Clerici M, et al. Immunological and clinical effect of diet modulation of the gut microbiome in multiple sclerosis patients: a pilot study. Front Immunol. 2017;8:1391. doi:10.3389/fimmu.2017.01391.
   PubMed Web of Science ®Google Scholar
• Wahls TL, Titcomb TJ, Bisht B, Eyck PT, Rubenstein LM, Carr LJ, Darling WG, Hoth KF, Kamholz J, Snetselaar LG, et al. Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: the WAVES randomized parallel-arm clinical trial. Mult Scler J Exp Transl Clin. 2021;7(3):20552173211035399. doi:10.1177/20552173211035399.
   Google Scholar
• Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017;7:1–18. doi:10.2147/DNND.S116949.
   PubMed Web of Science ®Google Scholar
• Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, Riddehough A, Li DKB, McDougall J, Lovera J, et al. Low-fat, plant-based diet in multiple sclerosis: a randomized controlled trial. Mult Scler Relat Disord. 2016;9:80–90. doi:10.1016/j.msard.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Halkjaer SI, Boolsen AW, Gunther S, Christensen AH, Petersen AM. Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol. 2017;23(22):4112–4120. doi:10.3748/wjg.v23.i22.4112.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228. doi:10.1016/S0140-6736(17)30182-4.
   PubMed Web of Science ®Google Scholar
• Xue LJ, Yang X-Z, Tong Q, Shen P, Ma S-J, Wu S-N, Zheng J-L, Wang H-G. Fecal microbiota transplantation therapy for Parkinson’s disease: a preliminary study. Med. 2020;99(35):e22035. doi:10.1097/MD.0000000000022035.
   PubMed Web of Science ®Google Scholar
• Mao D, Jiang Q, Sun Y, Mao Y, Guo L, Zhang Y, Man M, Ouyang G, Sheng L. Treatment of intestinal graft-versus-host disease with unrelated donor fecal microbiota transplantation capsules: a case report. Med. 2020;99(38):e22129. doi:10.1097/MD.0000000000022129.
   PubMed Web of Science ®Google Scholar
• Li K, Wei S, Hu L, Yin X, Mai Y, Jiang C, Peng X, Cao X, Huang Z, Zhou H, et al. Protection of fecal microbiota transplantation in a mouse model of multiple sclerosis. Mediators Of Inflammation. 2020;2020:1–13. doi:10.1155/2020/2058272.
   Web of Science ®Google Scholar
• Makkawi S, Camara-Lemarroy C, Metz L. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e459. doi:10.1212/NXI.0000000000000459.
   PubMed Web of Science ®Google Scholar
• Engen PA, Zaferiou A, Rasmussen H, Naqib A, Green SJ, Fogg LF, Forsyth CB, Raeisi S, Hamaker B, Keshavarzian A, et al. Single-arm, non-randomized, time series, single-subject study of fecal microbiota transplantation in multiple sclerosis. Front Neurol. 2020;11:978. doi:10.3389/fneur.2020.00978.
   PubMed Web of Science ®Google Scholar
• Al KF, Craven LJ, Gibbons S, Parvathy SN, Wing AC, Graf C, Parham KA, Kerfoot SM, Wilcox H, Burton JP, et al. Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: a pilot randomized controlled trial. Mult Scler J Exp Transl Clin. 2022;8(2):20552173221086662. doi:10.1177/20552173221086662.
   Google Scholar
• Tanasescu R, Tench CR, Constantinescu CS, Telford G, Singh S, Frakich N, Onion D, Auer DP, Gran B, Evangelou N, et al. Hookworm treatment for relapsing multiple sclerosis: a randomized Double-blinded placebo-controlled trial. JAMA Neurol. 2020;77(9):1089–1098. doi:10.1001/jamaneurol.2020.1118.
   PubMed Web of Science ®Google Scholar
• Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011;233(1–2):6–11. doi:10.1016/j.jneuroim.2011.01.002.
   PubMed Web of Science ®Google Scholar
• Jenkins TP, Pritchard DI, Tanasescu R, Telford G, Papaiakovou M, Scotti R, Cortés A, Constantinescu CS, Cantacessi C. Experimental infection with the hookworm, necator americanus, is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis. BMC Biol. 2021;19(1):74. doi:10.1186/s12915-021-01003-6.
   PubMed Web of Science ®Google Scholar
• Barone M, Mendozzi L, D’Amico F, Saresella M, Rampelli S, Piancone F, La Rosa F, Marventano I, Clerici M, d’Arma A, et al. Influence of a high-impact multidimensional rehabilitation program on the gut microbiota of patients with multiple sclerosis. Int J Mol Sci. 2021;22(13):7173. doi:10.3390/ijms22137173.
   PubMed Web of Science ®Google Scholar